0001437749-26-010339
SEC filingFiscal 2025 delivered meaningful operational and financial progress for ImmuCell, marked by positive operating income and expanded margins as we prioritized core animal health product lines.
ImmuCell’s adjusted strategy for its Re-Tain® product eliminates the need for further capital investment in in-house manufacturing capability for the line, freeing up operational and financial resources to focus on maximizing the value of the First Defense® franchise. Management expects to allocate available capital to core product development, facility and production equipment upgrades, and expanded working capital to support ongoing demand for its leading offerings.